Pipeline

Aramis Biosciences was founded to revolutionize the standard of care in ocular immunology, beginning with Dry Eye Disease.

Candidate	Indication	Preclinical IND Phase 1 Phase 2 Phase 3
	Dry Eye Disease
A197
	Other Immuno‑Inflammatory Ocular Disease